Brief: MaxCyte Says Nasdaq Listing Unaffected By AIM Delisting - SEC Filing
June 25 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE INC: HAD APPLIED TO LSE TO CANCEL ITS ADMISSION OF CO'S COMMON STOCK TO TRADING ON AIM MARKET OF LSE MAXCYTE INC - NASDAQ LISTING UNAFFECTED BY AIM DELISTING - SEC FILING Source text: [ID:n0001558370-25-008856] Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026